

1 STATE OF OKLAHOMA

2 2nd Session of the 53rd Legislature (2012)

3 SENATE BILL 1823

By: Bingman

4
5
6 AS INTRODUCED

7 An Act relating to the Oklahoma Health Care
8 Authority; amending 63 O.S. 2011, Section 5030.4A,
9 which relates to a study of disease management
10 programs; modifying reporting requirements; and
11 providing an effective date.

12 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

13 SECTION 1. AMENDATORY 63 O.S. 2011, Section 5030.4A, is
14 amended to read as follows:

15 Section 5030.4A. A. The Oklahoma Health Care Authority shall
16 study the feasibility of implementing one or more disease state
17 management programs.

18 B. The components of the study shall include, but not be
19 limited to:

20 1. A description and assessment of the findings, costs of the
21 program, savings incurred and estimated costs and savings of an
22 expansion of the pilot program for asthma disease state management
23 developed by the Authority;

1 2. An overview of disease state management programs for
2 enrollees of health management organizations contracting with the
3 Authority pursuant to the Sooner Care Plus Program;

4 3. An assessment of the adaptability of such disease state
5 management programs for the Medicaid fee-for-service population;

6 4. An overview of representative vendors of the disease state
7 management programs, including their characteristics, capabilities
8 and charges for products and services;

9 5. An overview and assessment of the disease state management
10 pilot project developed by the Oklahoma State Education Employees
11 Government Insurance Board; and

12 6. A record, if available, of the savings generated by disease
13 state management programs in other states by pharmaceutical
14 manufacturers for Medicaid fee-for-service recipients.

15 C. The study shall be under the joint direction of the Disease
16 State Management Director and the Pharmacy Director of the Oklahoma
17 Health Care Authority. The Directors shall consult with the
18 following entities as they deem necessary:

19 1. Medical, pharmacy, and nursing professionals who are
20 experienced in disease state management programs;

21 2. Appropriate pharmaceutical manufacturers in connection with
22 study components outlined in paragraphs 4 and 5 of subsection B of
23 this section;

24 3. Disease state management vendors; and

1 4. Other resources as necessary including, but not limited to,
2 health care advocates.

3 D. The Oklahoma Health Care Authority shall submit ~~periodic~~
4 progress reports on or before December 31 of each year to the ~~Joint~~
5 ~~Legislative Oversight Committee.~~ ~~The Oklahoma Health Care Authority~~
6 ~~shall publish and submit a final report by December 1, 2002, to the~~
7 ~~Speaker of the Oklahoma House of Representatives, the President Pro~~
8 ~~Tempore of the Senate, the Governor, and the chair of the Health and~~
9 ~~Social Services Subcommittee of the Appropriation and Budget~~
10 ~~Committee of the Oklahoma House of Representatives and of the Health~~
11 ~~and Social Services Subcommittee of the Committee on Appropriations~~
12 ~~of the Oklahoma State Senate~~ Governor, the President Pro Tempore of
13 the Senate and the Speaker of the House of Representatives.

14 E. As used in this section, "disease state management program"
15 means an integrated system of interventions, measurements and
16 refinements of health care delivery that include:

- 17 1. Patient education and involvement in self-care techniques;
- 18 2. Clinical policies/best practices that extend across the
19 entire continuum of care;
- 20 3. Outpatient drug management;
- 21 4. Clinical information systems with the capacity to identify,
22 classify, and track defined patient populations;
- 23 5. Informed support of physicians;
- 24 6. Team-oriented multidisciplinary approach; and

1 7. Feedback or continuous review.

2 SECTION 2. This act shall become effective November 1, 2012.

3
4 53-2-2966 JM 1/19/2012 6:58:09 PM
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24